Iodoquinazoline-derived VEGFR-2 and EGFRT790M dual inhibitors: Design, synthesis, molecular docking and anticancer evaluations
AA Mohamed, SSA El-Hddad, AKB Aljohani… - Bioorganic …, 2024 - Elsevier
Herein, we report the synthesis of a series of new fourteen iodoquinazoline derivatives 7a-c
to 13a-e and their evaluation as potential anticancer agents via dual targeting of EGFR …
to 13a-e and their evaluation as potential anticancer agents via dual targeting of EGFR …
[HTML][HTML] Design, synthesis, docking, ADMET and anticancer evaluations of N-alkyl substituted iodoquinazoline derivatives as dual VEGFR-2 and EGFR inhibitors
Fifteen new 1-alkyl-6-iodoquinazoline derivatives 5a–d to 9a–e were designed and
synthesized and their anticancer activities were evaluated against HepG2, MCF-7, HCT116 …
synthesized and their anticancer activities were evaluated against HepG2, MCF-7, HCT116 …
[HTML][HTML] Anticancer evaluations of iodoquinazoline substituted with allyl and/or benzyl as dual inhibitors of EGFR WT and EGFR T790M: design, synthesis, ADMET …
Fifteen new iodoquinazoline derivatives, 5a, b to 18, are reported in this study and their
anticancer evaluation as dual inhibitors of EGFRWT and EGFRT790M. The new derivatives …
anticancer evaluation as dual inhibitors of EGFRWT and EGFRT790M. The new derivatives …
[HTML][HTML] New quinoxaline-based VEGFR-2 inhibitors: Design, synthesis, and antiproliferative evaluation with in silico docking, ADMET, toxicity, and DFT studies
A new series of 3-methylquinoxaline-based derivatives having the same essential
pharmacophoric features as VEGFR-2 inhibitors have been synthesized and evaluated for …
pharmacophoric features as VEGFR-2 inhibitors have been synthesized and evaluated for …
Novel 4-Anilinoquinazoline Derivatives as Potent Anticancer Agents: Design, Synthesis, Cytotoxic Activity, and Docking Study
FA Moghadam, S Dabirian, MG Dogaheh… - Australian Journal of …, 2021 - CSIRO Publishing
The simultaneous inhibition of EGFR and VEGFR-2 is a promising method in cancer
treatment. In the present work, several 4-anilinoquinazoline derivatives encompassing …
treatment. In the present work, several 4-anilinoquinazoline derivatives encompassing …
Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2
HQ Zhang, FH Gong, JQ Ye, C Zhang, XH Yue… - European Journal of …, 2017 - Elsevier
EGFR and VEGFR-2 are involved in pathological disorders and the progression of different
kinds of tumors, the combined blockade of EGFR and VEGFR signaling pathways appears …
kinds of tumors, the combined blockade of EGFR and VEGFR signaling pathways appears …
New quinoxaline-2 (1 H)-ones as potential VEGFR-2 inhibitors: Design, synthesis, molecular docking, ADMET profile and anti-proliferative evaluations
Eleven new quinoxaline derivatives were designed and synthesized as modified VEGFR-2
inhibitors of our previous work. The synthesized compounds were tested against three …
inhibitors of our previous work. The synthesized compounds were tested against three …
Pyrazolo [3, 4-d] pyrimidine derivatives as EGFRT790M and VEGFR-2 dual TK inhibitors: Design, synthesis, molecular docking, ADMET profile and anticancer …
Abstract Seventeen new pyrazolo [3, 4-d] pyrimidine derivatives have been designed,
created and tested as dual VEGFR-2 and EGFR inhibitors for their anticancer special effects …
created and tested as dual VEGFR-2 and EGFR inhibitors for their anticancer special effects …
Design, synthesis, in vitro antiproliferative evaluation and in silico studies of new VEGFR-2 inhibitors based on 4-piperazinylquinolin-2 (1H)-one scaffold
Angiogenesis is essential in the growth of solid tumors which need oxygen and nutrients
supply to grow in size. The VEGF/VEGFR-2 signaling pathway plays an important role in …
supply to grow in size. The VEGF/VEGFR-2 signaling pathway plays an important role in …
Discovery of new 3-methylquinoxalines as potential anti-cancer agents and apoptosis inducers targeting VEGFR-2: design, synthesis, and in silico studies
There is an urgent need to design new anticancer agents that can prevent cancer cell
proliferation even with minimal side effects. Accordingly, two new series of 3 …
proliferation even with minimal side effects. Accordingly, two new series of 3 …